disease therapy articles & resources on Made-in-China.com

NovelMed Therapeutics Has Received a Combined $1.43m SBIR Grant

Sep 12, 2013

NovelMed Therapeutics has received a combined $1.43m small business innovation research (SBIR) grant from the National Institutes of Health (NIH) to further develop its anti-complement antibody for orphan disease. The company will use the ...

Tags: NovelMed, Medicine

The US FDA Has Cleared Eisai's ACIPHEX Sprinkle as 12-Week GERD Therapy

Mar 28, 2013

The US FDA has cleared Eisai's ACIPHEX Sprinkle (rabeprazole sodium) as 12-week gastroesophageal reflux disease (GERD) therapy for use in children between one to eleven years age. The approval was based on positive data from multicenter, ...

Tags: FDA, Disease Therapy for Children, Medicine

Pfizer and Protalix BioTherapeutics Have Obtained Approval for Uplyso

Mar 20, 2013

Pfizer and Protalix BioTherapeutics have obtained approval from the Brazilian National Health Surveillance Agency for Uplyso (alfataliglicerase) as type I Gaucher disease therapy. Uplyso, referred to as Elelyso (taliglucerase alfa) ...

Tags: Pfizer, Protalix, Protalix BioTherapeutics

TransTech Pharma Received FDA Fast Track Designation for TTP488

Mar 19, 2013

TransTech Pharma has received FDA fast track designation for new small-molecule chemical compound TTP488, for the treatment of Alzheimer's disease. TTP488 prevents interaction of a material found in the Alzheimer's patients cells, ...

Tags: Transtech Alzheimer, FDA, Medicine

The US FDA Granted Fast Track Status to Soligenix's SGX203 for The Treatment

Nov 9, 2012

The US FDA has granted fast track status to Soligenix's SGX203 for the treatment of pediatric Crohn's disease. SGX203 contains an active corticosteroid, beclomethasone 17,21-dipropionate (BDP), that targets local inflamed tissue. ...

Tags: fast track status, US FDA, pharmaceutical product

USPTO Grants Galectin Therapeutics a Notice of Issuance for a Patent

Jul 24, 2012

The USPTO has granted Galectin Therapeutics a notice of issuance for a patent covering methods of derivation and use for carbohydrate-based galectin inhibitor compound for use in patients with chronic liver disease associated with the ...

Tags: Galectin, US patent, disease therapy

Emmaus Are Committed to Bring a Treatment for This Severely Underserved Patient Population

Jun 18, 2012

Emmaus Medical, a subsidiary of Emmaus Life Sciences, has received European orphan medicinal product designation for Levoglutamide (L-glutamine) for the treatment of sickle cell disease. Emmaus is at present conducting a trial, at over 30 ...

Tags: sickle cell disease, clinical trial, product designation